84 related articles for article (PubMed ID: 8345196)
1. Synergism between IFN-gamma and IL-1 alpha/beta in growth inhibition of an allografted tumor.
Takikawa O; Oku T; Yasui H; Yoshida R
J Immunol; 1993 Aug; 151(4):2070-6. PubMed ID: 8345196
[TBL] [Abstract][Full Text] [Related]
2. IFN-gamma is the inducer of indoleamine 2,3-dioxygenase in allografted tumor cells undergoing rejection.
Takikawa O; Habara-Ohkubo A; Yoshida R
J Immunol; 1990 Aug; 145(4):1246-50. PubMed ID: 2116480
[TBL] [Abstract][Full Text] [Related]
3. Synergistic therapeutic effect of combination therapy with OK-432 and interferon-alpha or -gamma on Meth-A ascites tumor in BALB/c mice.
Mizushima Y; Morikage T; Hirata H; Sato M; Sakamoto K; Yano S
J Biol Response Mod; 1988 Aug; 7(4):371-83. PubMed ID: 3139841
[TBL] [Abstract][Full Text] [Related]
4. The role of T cells in allografted tumor rejection: IFN-gamma released from T cells is essential for induction of effector macrophages in the rejection site.
Yoneda Y; Yoshida R
J Immunol; 1998 Jun; 160(12):6012-7. PubMed ID: 9637516
[TBL] [Abstract][Full Text] [Related]
5. IFN-gamma- and cell-to-cell contact-dependent cytotoxicity of allograft-induced macrophages against syngeneic tumor cells and cell lines: an application of allografting to cancer treatment.
Yoshida R; Yoneda Y; Kuriyama M; Kubota T
J Immunol; 1999 Jul; 163(1):148-54. PubMed ID: 10384111
[TBL] [Abstract][Full Text] [Related]
6. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
7. Interferon-gamma-dependent expression of inducible nitric oxide synthase, interleukin-12, and interferon-gamma-inducing factor in macrophages elicited by allografted tumor cells.
Sanchez-Bueno A; Verkhusha V; Tanaka Y; Takikawa O; Yoshida R
Biochem Biophys Res Commun; 1996 Jul; 224(2):555-63. PubMed ID: 8702426
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effect of recombinant human interferon-beta and interferon-gamma in combination against human colon cancer cell line in vitro and in nude mice.
Kondo H; Tanaka N; Naomoto Y; Orita K
Jpn J Cancer Res; 1987 Nov; 78(11):1258-65. PubMed ID: 3121561
[TBL] [Abstract][Full Text] [Related]
9. Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha.
Musiani P; Allione A; Modica A; Lollini PL; Giovarelli M; Cavallo F; Belardelli F; Forni G; Modesti A
Lab Invest; 1996 Jan; 74(1):146-57. PubMed ID: 8569177
[TBL] [Abstract][Full Text] [Related]
10. Ca2+-dependent, Fas- and perforin-independent apoptotic death of allografted tumor cells by a type of activated macrophage.
Yoshida R; Sanchez-Bueno A; Yamamoto N; Einaga-Naito K
J Immunol; 1997 Jul; 159(1):15-21. PubMed ID: 9200433
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-4 (IL-4) in combination with IL-11 or IL-6 reverses the inhibitory effect of IL-3 on early B lymphocyte development.
Neben S; Donaldson D; Fitz L; Calvetti J; Neben T; Turner K; Hirayama F; Ogawa M
Exp Hematol; 1996 Jun; 24(7):783-9. PubMed ID: 8647228
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of tumor growth by the intralesional administration of interleukin-3 into mice implanted with solid tumors.
Sasaki H; Schmitt DA; Hayashi Y; Pollard RB; Suzuki F
Anticancer Res; 1992; 12(2):313-5. PubMed ID: 1580549
[TBL] [Abstract][Full Text] [Related]
13. Cell-associated human retinal pigment epithelium interleukin-8 and monocyte chemotactic protein-1: immunochemical and in-situ hybridization analyses.
Elner VM; Burnstine MA; Strieter RM; Kunkel SL; Elner SG
Exp Eye Res; 1997 Dec; 65(6):781-9. PubMed ID: 9441701
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-gamma: a role for intrinsic tumor immunogenicity and IL-15.
Gri G; Chiodoni C; Gallo E; Stoppacciaro A; Liew FY; Colombo MP
Cancer Res; 2002 Aug; 62(15):4390-7. PubMed ID: 12154045
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon gamma: mechanism of action and potential for combination with interleukin 4.
Hillman GG; Younes E; Visscher D; Hamzavi F; Kim S; Lam JS; Montecillo EJ; Ali E; Pontes JE; Puri RK; Haas GP
Clin Cancer Res; 1997 Oct; 3(10):1799-806. PubMed ID: 9815566
[TBL] [Abstract][Full Text] [Related]
16. IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects.
Osaki T; Péron JM; Cai Q; Okamura H; Robbins PD; Kurimoto M; Lotze MT; Tahara H
J Immunol; 1998 Feb; 160(4):1742-9. PubMed ID: 9469432
[TBL] [Abstract][Full Text] [Related]
17. [Expression of non-T cell derived cytokines in acute rejection after heart transplantation: experiment with mouse model].
Liang TB; Yu ZY; Zheng SS
Zhonghua Yi Xue Za Zhi; 2006 Jan; 86(1):26-30. PubMed ID: 16606531
[TBL] [Abstract][Full Text] [Related]
18. Alpha 1-interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice: antitumor therapy by means of interferon-producing cells.
Ferrantini M; Proietti E; Santodonato L; Gabriele L; Peretti M; Plavec I; Meyer F; Kaido T; Gresser I; Belardelli F
Cancer Res; 1993 Mar; 53(5):1107-12. PubMed ID: 8439955
[TBL] [Abstract][Full Text] [Related]
19. Defense mechanisms of IFN-gamma and LPS-primed murine microglia against Acanthamoeba castellanii infection.
Benedetto N; Rossano F; Gorga F; Folgore A; Rao M; Romano Carratelli C
Int Immunopharmacol; 2003 Jun; 3(6):825-34. PubMed ID: 12781699
[TBL] [Abstract][Full Text] [Related]
20. Herpes simplex virus type 1 alters transcript levels of tumor necrosis factor-alpha and interleukin-6 in retinal glial cells.
Drescher KM; Whittum-Hudson JA
Invest Ophthalmol Vis Sci; 1996 Oct; 37(11):2302-12. PubMed ID: 8843914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
